BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences
September 03, 2021 08:00 ET
|
BioDelivery Sciences International
RALEIGH, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Reports Second Quarter 2021 Results
August 04, 2021 08:00 ET
|
BioDelivery Sciences International
Total Company Net Revenue of $41.4 Million Driven by BELBUCA® All-Time High TRx Market Share Strong Profitability with GAAP Net Income of $9.1 Million, or $0.09 per share, EBITDA Margin of 32%, and...
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine
August 04, 2021 07:30 ET
|
BioDelivery Sciences International
The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults First step to building a growth platform in Neurology Patent protection until...
BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021
July 22, 2021 08:00 ET
|
BioDelivery Sciences International
RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
BioDelivery Sciences Reports First Quarter 2021 Results
May 06, 2021 08:00 ET
|
BioDelivery Sciences International
Total Company Net Revenue of $41 Million, an Increase of 7% versus Prior Year Net Income of $5.2 Million, EBITDA Margin of 22% and Operating Cash Generation of $11 MillionConference Call and Webcast...
BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021
April 20, 2021 08:00 ET
|
BioDelivery Sciences International
RALEIGH, N.C., April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results
March 10, 2021 08:00 ET
|
BioDelivery Sciences International
Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million, Full-Year EBITDA Margin of 26% and...
BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021
February 17, 2021 08:00 ET
|
BioDelivery Sciences International
RALEIGH, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
BioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice President
February 11, 2021 08:00 ET
|
BioDelivery Sciences International
RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic...
BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting
January 15, 2021 09:00 ET
|
BioDelivery Sciences International
Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory OutcomesComparing BELBUCA® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C., Jan. 15, 2021 (GLOBE...